Cabaletta Bio reports phase 1/2 data for autoimmune therapy

🌐 Investing.com (Cyprus) —
Cabaletta Bio reports phase 1/2 data for autoimmune therapy

AI Summary

Cabaletta Bio reported Phase 1/2 clinical data for an experimental therapy targeting autoimmune disease. The headline does not specify the treatment, results, or safety findings.

Markets Health Cabaletta Bio clinical trial Phase 1/2 autoimmune disease therapy biotechnology

Read original source →